SCHEMBL6035640

SCHEMBL6035640

Cc1nccc(CO)c1OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
GAA P10253 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
ATP4A P20648 1/20 0.42
ATP4B P51164 1/20 0.42
MAOA P21397 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.40
STAT3 P40763 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HTR1D P28221 1/20 0.40
HTR1B P28222 1/20 0.40
PTPN1 P18031 1/20 0.40
PTGER1 P34995 1/20 0.39
PTGER4 P35408 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6034939 0.84 PRMT5 (0.47) LMNAGAAKDM4EALDH1A1POLB
SCHEMBL4360270 0.83 KMT2A (0.42) LMNAGAAL3MBTL1MAPTMAPK1
SCHEMBL4149747 0.81 LMNA (0.48) LMNAGAAL3MBTL1MAOAMAPT
SCHEMBL5664859 0.80 L3MBTL1 (0.44) LMNAGAAL3MBTL1ATP4AATP4B
SCHEMBL20502645 0.79 HPGD (0.49) LMNAGAAL3MBTL1ATP4AATP4B
SCHEMBL4898749 0.79 L3MBTL1 (0.53) LMNAGAAL3MBTL1ATP4AATP4B
SCHEMBL9682836 0.78 LMNA (0.45) LMNAGAAL3MBTL1MAOAMAPT
SCHEMBL14193606 0.78 PTGER4 (0.60) L3MBTL1MAPTMAPK1TDP1KDM4E
SCHEMBL15088142 0.77 LMNA (0.54) LMNAGAAL3MBTL1ATP4AATP4B
SCHEMBL13107701 0.77 PDXK (0.54) LMNAGAAL3MBTL1ATP4AATP4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 LMNA 1816/4885GAA 815/4885L3MBTL1 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.